MannKind Corporation (MNKD) — closed signal from February 24, 2026
Partial Published before the outcome was known, scored automatically when the window closed on May 25, 2026.
Predicted vs. what happened
What happened
Reached 2% of the predicted growth at its peak, without hitting the target.
The thesis — published February 24, 2026
The stock could move fast in the next few weeks because the CEO will speak at a healthcare investor meeting and there is an ongoing pediatric review for Afrezza plus study plans. If the news looks better than feared, traders may push the price up, but that move can evaporate quickly without follow-through. Use small trade sizes and treat this as a short-term, event-driven idea.
Primary drivers
- Near-term attention can bring more trading and higher volume
- Regulatory news can quickly change what investors expect
- If sentiment improves, an oversold stock can jump back fast
- Small position sizes limit losses if the event goes poorly
How it played out
MNKD: the target was never reached
Lyra published MNKD at 5.70 on 2026-02-24 as a short-term, event-driven idea with expected growth of 30%. The thesis pointed to near-term attention from a healthcare investor meeting, an ongoing pediatric review for Afrezza, study plans, possible sentiment repair, and small position sizes because the move could fade without follow-through.
Inside the 2026-02-24 to 2026-05-25 window, MNKD peaked at 5.74 on 2026-02-24, a 0.7% gain. That stayed below the 7.40 target. It never got there. The stock ended the window at 3.38. The published thesis missed.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.